CVS, Cigna and UnitedHealth
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...
Zacks.com on MSN2h
FTC Report Reveals PBM Practices Impacting Competition and Drug CostsThe Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs. FTC’s report ...
WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain ...
CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging ...
Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and ...
The Health Care Benefits segment includes Aetna and other health insurance businesses. CVS acquired Aetna in 2017. In 2023, ...
CVS Caremark will add Zydus' ZituvioTM and combination products to its template formulary starting January 1, 2025 ...
Bernstein analyst Lance Wilkes maintained a Hold rating on CVS Health (CVS – Research Report) yesterday and set a price target of $52.00. The ...
Zydus Lifesciences has partnered with CVS Caremark to add its diabetes medications, Zituvio, Zituvimet, and Zituvimet XR, to ...
The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback